Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 2, 2011, Pages 221-227

  Lok, Anna Suk Fong ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Chronic hepatitis B; Chronic hepatitis C; Cirrhosis; Hepatitis B vaccine; Interferon treatment; Nucleos(t)ide analogs; Vaccination

Indexed keywords

ADEFOVIR; HEPATITIS B VACCINE; HEPATITIS C VACCINE; INTERFERON; LAMIVUDINE; PLACEBO; RIBAVIRIN;

ANTIVIRAL THERAPY; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 78851469544     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06576.x     Document Type: Article

References (28)

1. Okuda K. Hepatocellular carcinoma. J. Hepatol. 2000; 32: 225-37.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005; 55: 74-108.
3. Chang M, You S, Chen C etal. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J. Natl. Cancer Inst. 2009; 101: 1348-55.
4. Yang HI, Lu SN, Liaw YF etal. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N. Engl. J. Med. 2002; 347: 168-74.
5. Yu MW, Yeh SH, Chen PJ etal. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J. Natl. Cancer Inst. 2005; 97: 265-72.
6. Chen CJ, Yang HI, Su J etal. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295: 65-73.
7. Iloeje U, Yang H, Su J, Jen C, You S, Chen C. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
8. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971-5.
9. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment. Pharmacol. Ther. 2008; 28: 1067-77.
10. Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001; 34: 139-45.
11. Lin SM, Yu ML, Lee CM etal. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J. Hepatol. 2007; 46: 45-52.
12. Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2004; 127: S303-9.
13. Liaw YF, Sung JJ, Chow WC etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004; 351: 1521-31.
14. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J. Hepatol. 2010; 53: 348-56.
15. Camma C, Di Bona D, Schepis F etal. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004; 39: 333-42.
16. Nishiguchi S, Kuroki T, Nakatani S etal. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
17. Singal AK, Singh A, Jaganmohan S etal. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin. Gastroenterol. Hepatol. 2010; 8: 192-9.
18. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment. Pharmacol. Ther. 2001; 15: 689-98.
19. Craxi A, Camma C. Prevention of hepatocellular carcinoma. Clin. Liver Dis. 2005; 9: 329-46.
20. Bruno S, Stroffolini T, Colombo M etal. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-87.
21. Morgan TR, Ghany MG, Kim HY etal. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-44.
22. Imai Y, Kawata S, Tamura S etal. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann. Intern. Med. 1998; 129: 94-9.
23. Yu ML, Lin SM, Chuang WL etal. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir. Ther. 2006; 11: 985-94.
24. Di Bisceglie AM, Shiffman ML, Everson GT etal. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008; 359: 2429-41.
25. Afdhal NH, Levine R, Brown RS, Freilich B, O'Brien M, Brass C. Colchichine versus peg-interferon alfa-2b long term therapy: results of the 4year copilot trial. J. Hepatol. 2008; 48: S4.
26. Bruix J, Poynard T, Colombo M etal. Pegintron maintenance therapy in Cirrhotic (Metavir F4) HCV patients, who failed to respond to Interferon/Ribavirn (IR) therapy: final results of the Epic3 cirrhosis maintenance trial (abstract 49). J. Hepatol. 2009; 50: S22.
27. Lok AS, Seeff LB, Morgan TR etal. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136: 138-48.
28. Lok AS, Everhart JE, Wright EC, Morgan TR, Di Bisceglie AM, Kim H. Maintenance peginterferon (pegIFN) therapy to prevent hepatocellular carcinoma (HCC) in patients (pts) with advanced chronic hepatitis C (CHC): extended follow-up results from the HALT-C Trial (abstract). AASLD Abstract. 2010.